Gilead Sciences (GILD) Cash & Equivalents (QoQ) (2009 - 2026)

Gilead Sciences (GILD) Cash & Equivalents (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 0.85%
Dec 31, 2025 3.19%
Sep 30, 2025 42.50%
Jun 30, 2025 -35.10%
Mar 31, 2025 -20.67%
Dec 31, 2024 98.35%
Sep 30, 2024 81.71%
Jun 30, 2024 -41.25%
Mar 31, 2024 -22.47%
Dec 31, 2023 6.66%
Sep 30, 2023 0.02%
Jun 30, 2023 15.56%
Mar 31, 2023 -8.80%
Dec 31, 2022 15.17%
Sep 30, 2022 -0.84%
Jun 30, 2022 10.31%
Mar 31, 2022 -19.52%
Dec 31, 2021 22.38%
Sep 30, 2021 -10.85%
Jun 30, 2021 20.37%